Key clinical point: Ixazomib may reduce treatment failure in patients with advanced chronic graft-versus-host disease.
Major finding: The 6-month treatment failure rate was significantly lower in this trial than in historical controls – 28% and 44%, respectively (P = .01).
Study details: A phase 2 trial of 50 patients with hematologic malignancies.
Disclosures: The trial was sponsored by the Fred Hutchinson Cancer Research Center in collaboration with the National Cancer Institute. The investigators reported relationships with Pfizer, CSL Behring, Agios, Incyte, Genentech, and Takeda.
Pidala J et al. TCT 2019, Abstract 35.
This Week's Must Reads
Must Reads in Cellular Therapy
Haplo-HCT shows viability in DLBCL, Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9